Zomedica reels in $4M for pet drug development

Michigan-based Zomedica, a relatively new company focused on developing pet meds and complementary products, has reeled in C$5 million ($4 million) as the first part of a share placement offering.

Formed in May 2015, Zomedica is working on an antibiotic for pets, as well as a drug to treat metabolic disorders. The money represents the first tranche of what the executive team hopes will be C$15 million ($11.7 million) raised to advance its pipeline and pay for other activities such as IP protection and potential acquisitions.

Zomedica CEO Gerald Solensky Jr. told Crain’s Detroit he expects the fundraising to finish in about a month. Zomedica is listed on the Venture Exchange of the Toronto Stock Exchange and raised $7 million before going public, Crain’s reports.

In addition to developing drugs for animals, Zomedica is looking to enter the booming markets for diagnostics and devices through M&A or in-licensing, according to its website.

Zomedica is not alone in its focus on developing novel pet therapeutics as alternatives to the repurposed human drugs that are so widely used by veterinarians. And there are plenty of companies out there looking to in-license innovative products. Aratana Therapeutics ($PETX) is currently on a licensing push, and other companies such as VetDC, Kindred Biosciences ($KIN) and CanFel are working in the space, too, Crain's notes. 

Elsewhere in animal health, startups have remained active recently thanks to private funding in areas ranging from pet diagnostics to insurance. In just over a year, companies Rex, Petnostics and Figo each drummed up funding to get underway with their ideas. And in April, startup Embark started marketing its $199 DNA test for dogs.

- here’s the release
- see more from Crain’s

Related Articles:
Startup Rex clears $1M, starts hiring in KC Animal Health Corridor
Petnostics nabs $300,000 on Shark Tank for at-home pet urine test
Figo brings home $4M to spur development of mobile tech for pet owners
Startup Embark offers detailed DNA testing for dogs

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.